Abstract This work describes a liquid chromatographyelectrospray tandem mass spectrometry method for detection of desmopressin in human plasma in the low femtomolar range. Desmopressin is a synthetic analogue of the antidiuretic hormone arginine vasopressin and it might be used by athletes as a masking agent in the framework of blood passport controls. Therefore, it was recently added by the World Anti-Doping Agency to the list of prohibited substances in sport as a masking agent. Mass spectrometry characterization of desmopressin was performed with a high-resolution Orbitrap-based mass spectrometer. Detection of the peptide in the biological matrix was achieved using a triple-quadrupole instrument with an electrospray ionization interface after protein precipitation, weak cation solid-phase extraction and high performance liquid chromatography separation with an octadecyl reverse-phase column. Identification of desmopressin was performed using three product ions, m/z 328.0, m/z 120.0, and m/z 214.0, from the parent ion, m/z 535.5. The extraction efficiency of the method at the limit of detection was estimated as 40% (n010), the ion suppression as 5% (n010), and the limit of detection was 50 pg/ml (signal-to-noise ratio greater than 3). The selectivity of the method was verified against several endogenous and synthetic desmopressin-related peptides. The performance and the applicability of the method were tested by analysis of clinical samples after administration of desmopressin via intravenous, oral, and intranasal routes. Only after intravenous administration could desmopressin be successfully detected.
Introduction
Desmopressin, 1-desamino-8-D-arginine-vasopressin, is a synthetic analogue of arginine [Arg important hematological parameters used to detect blood doping in sports [15, 16] . Therefore, desmopressin was recently added by the World Anti-Doping Agency (WADA) to the 2011 Prohibited List as a masking agent [17] .
Previous methods for the detection of desmopressin in biological fluids were performed only for clinical purposes, by immunoassays. These methods provided sensitive and cost-effective analyses [8, [18] [19] [20] [21] [22] , but with some important limitations, in particular concerning specificity [23] .
Liquid chromatography (LC)-mass spectrometry (MS) shows good sensitivity together with a high degree of selectivity and specificity to allow unequivocal confirmation of the presence of a substance on the basis of its molecular weight. Hence, LC-MS methods have become the method of choice for the analysis of peptides [24] .
Until now, only one study using LC-MS to identify desmopressin has been published [25] . This method was applied for the analysis of skin samples and has a limit of detection (LOD) of 10 ng/ml (approximately 10 pmol). Obviously, this matrix is not applicable in the field of sports drug testing. Hence, the present work had the aim to develop and validate an LCelectrospray ionization (ESI) MS/MS method for detection of desmopressin in plasma fit for antidoping purposes.
Materials and methods

Chemicals and reagents
All the chemicals and solvents used for sample pretreatment and chromatography were analytical grade or highperformance LC (HPLC) grade. Desmopressin was a kind gift from Ferring Pharmaceuticals (Malmö, Sweden). AVP and [deamino-Cys ]-vasopressin, and terlipressin were purchased from Selleck Chemicals (Houston, USA). Desmopressin and the analogues were all available as acetate salts. The stock and working solutions were all prepared using 2% acetic acid (HOAc) aqueous solutions. Acetonitrile (ACN) and water were purchased from BioSolve (Lexington, USA); methanol (MeOH) was purchased from Fisher Scientific (Aalst, Belgium); 25% ammonia aqueous solution (NH 4 OH) and glacial HOAc were purchased from Merck (Darmstadt, Germany); trifluoroacetic acid (TFA) was purchased from Sigma-Aldrich.
Saturated ammonium sulfate, (NH 4 ) 2 SO 4 , solution was prepared by dissolving 800 g of (NH 4 ) 2 SO 4 (Merck, Darmstadt, Germany) in 1,000 ml of H 2 O at room temperature. The resulting solution was gently poured into a second glass bottle to get rid of the undissolved crystals of (NH 4 ) 2 SO 4 , then 20 ml of 25% NH 4 OH was added to 1 l of the (NH 4 ) 2 SO 4 solution.
Only low-binding microcentrifugal vials, Eppendorf type (Eppendorf, Hamburg, Germany), and low-retention pipette tips (Sorenson Biosciences, Salt Lake City, USA) were used to prepare stock solutions (100 μg/ml) and working solutions (10 ng/ml). AVP was always added to desmopressin working solutions at a concentration of 2.5 ng/mL, in order to prevent adsorption of desmopressin to solid surfaces.
Plasma/serum samples Method development and validation were performed using leftover plasma and serum samples obtained from the Red Cross Blood Transfusion Center (Ghent, Belgium, approval number 20100609). Desmopressin-containing plasma samples were obtained from the Department of Internal Medicine (Endocrinology and Hematology) of Ghent University hospital, with the approval of the Ethical Committee of Ghent University (reference B67020108809). ]-vasopressin (50 ng/ml) as an internal standard. Then, 2 ml of saturated (NH 4 ) 2 SO 4 solution, containing 2% NH 4 OH, was added and the samples were centrifuged (4,100g, 1 h, 2°C) to precipitate plasma proteins. A further purification of the supernatant was performed by solid-phase extraction (SPE) with Oasis® WCX (60 mg) cartridges, purchased from Waters (Milford, USA). The column was first activated with 2 ml of MeOH and was subsequently rinsed with 2 ml of H 2 O. After the sample had been loaded, the column was washed first with 2 ml of 5% NH 4 Scientific, Bremen, Germany) using a Zorbax 300SB-C18 reverse-phase column (1.0 mm×50 mm, 3.5 μm) protected with a Zorbax 300SB-C8 guard column, both from Agilent Technologies (Santa Clara, USA). The use of the C 8 guard column was adopted from previous work by Thevis et al. [26] . For each sample, 30 μl was injected. A binary gradient was used: mobile phase A consisted of H 2 O, 0.1% HOAc, 0.01% TFA; mobile phase B consisted of ACN, 0.1% HOAc, 0.01% TFA. Gradient elution was as follows: 95% mobile phase A for 1.5 min, then decreased linearly to 0% mobile phase A in 8.5 min, and held at 0% mobile phase A for 5 min, followed by an increase to 95% mobile phase A in 0.1 min. Then the system was equilibrated for 10 min before the next injection (total run time 25 min). A constant flow rate of 50 μl/min was maintained.
Mass spectrometry MS/MS method development for detection of desmopressin in human plasma was performed with a TSQ Quantum Discovery triple-stage quadrupole mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with an ESI source operating in positive mode The ESI-MS operating variables used were as follows: capillary voltage, 3.5 kV; source temperature, 350°C; sheath gas pressure, 30 psi; auxiliary gas pressure, 10 psi; tube lens offset, 84 V.
MS characterization of desmopressin and related peptides was performed with an Exactive benchtop Orbitrap-based mass spectrometer (Thermo Scientific, Bremen, Germany) operating in positive high-energy collisional dissociation (HCD) scan mode at 50 eV. The sheath gas was set to 60 (arbitrary units), the auxiliary gas was set to 30 (arbitrary units), and the capillary temperature was set to 350°C. The capillary voltage and spray voltage were set to 30 V and 3 kV, respectively. The instrument was operated in full-scan mode from m/z 60 to m/z 1,200 at 100,000 resolving power. The data acquisition rate was 1 Hz.
Disulfide bridge reduction
To obtain additional information on the MS behavior of desmopressin, reduction of the disulfide bridge (Mpa1-Cys6) was performed by adding 200 μl of dithiothreitol in 0.2 mM ammonium acetate buffer at pH 5.5 (both from Sigma-Aldrich) to readily prepared solutions of the peptide and incubating the resulting solution for 30 min at 56°C.
Validation
In accordance with Eurachem validation guidelines [27] , ten human plasma samples were spiked at different levels (5, 10, 25, 50, 100 pg/ml) to determine the LOD.
The LOD was defined as the lowest level at which a compound could be identified in all ten plasma samples with the diagnostic ions present with a signal-to-noise (S/N) ratio greater than 3 and a retention time difference of less than 0.2 min from the reference.
Selectivity was tested by analyzing plasma samples spiked with desmopressin and its analogues at a concentration of 100 pg/ml.
The analogues included the endogenous hormones AVP and oxytocin, and the synthetic derivatives [deamino-Cys ]-vasopressin, and terlipressin. Specificity was tested during the validation procedure to check for the absence of endogenous interferences. The ten blank plasma samples used for determining the analytical performances of the method were extracted and analyzed as described above.
Additionally, a cross-validation between plasma and serum samples was performed by analyzing six plasma and six serum samples spiked at the LOD of the method in plasma.
Extraction efficiency and matrix effect
To evaluate the extraction efficiency, the ten negative plasma samples, used for the validation, were spiked with desmopressin at 50 pg/ml and were processed together with nonspiked plasma samples. The extracts of the nonspiked plasma samples were spiked after evaporation and before HPLC injection. After analysis, the peak areas obtained for the product ion at m/z 328.0 of the two sets of samples were compared.
The matrix effect was evaluated by comparing the peak areas (m/z 328.0) of the plasma samples spiked after extraction with a reference solution of desmopressin at 50 pg/ml, corresponding to 100% recovery (0% matrix effect).
Excretion studies
Seven plasma samples from patients who had received desmopressin were used in the study. Four patients received desmopressin intranasally (approximately 10 μg per dose), two received desmopressin orally (200 μg), and one received desmopressin intravenously (20 μg). Blood samples were immediately centrifuged and plasma was separated. When not directly analyzed, plasma samples were stored at below -20°C awaiting analysis.
Results and discussion
Mass spectrometry
Direct infusion of desmopressin and the analogues was performed to determine the best MS conditions for the design of the multiple reaction monitoring (MRM) method. A full-scan MS analysis was first performed to identify the most abundant precursor ions, and subsequently the collision energy was optimized for the most diagnostic fragments.
Desmopressin showed excellent ionization, due to the presence of an arginine residue (Arg 8 ), containing the guanidinium group with high proton affinity. The doubly charged ion [M+2H] 2+ was observed as a base peak for desmopressin (Fig. 2) but also for the analogues. The singly charged ion [M+H] + only achieved a relative abundance of 20%. The collision-induced dissociation of the species corresponding to the desmopressin base peak (m/z 535.5) led to the formation of several fragments. Fragment ions at m/z 328.0, m/z 120.0, and m/z 214.0 were selected as diagnostic. Several other product ions also present in the spectrum were also recorded during MS characterization, but they were not specific or not sensitive enough using a criterion of S/N greater than 3 to be considered for reliable detection. The other vasopressin-related peptides presented similar ESI spectra. Also, the ion [M+2H] 2+ appeared as a base peak in the full-scan MS spectra of each peptide. Additionally, the peptides presented several common fragments, but different precursor ions and retention times were observed; therefore, method selectivity was guaranteed. Results from infusion experiments for MS/MS optimization of the compounds investigated are summarized in Table 1 .
The three diagnostic ions selected for the MRM method were further investigated by high-resolution MS. The fragmentation pattern of the peptide generated by HCD at 50 eVat high resolution is depicted in Fig. 3a . All the relevant fragments are singly charged and some of them show a neutral loss of NH 3 . Moreover, it is possible to see that all the significant high-mass fragments (y 2 -NH 3, y 3 -NH 3, y 3, b 6 ) contain Arg 8 . The b 6 -NH 3 fragment, which has an intramolecular disulfide bridge between C-1 and C-6 and is adjacent to a proline residue, represents the only exception [28] .
The contemporary presence in fragment ion y 3 of Arg 8 and Pro 6 at the N-terminal, which usually causes enhanced fragmentation attributed to the greater basicity of the proline substituted nitrogen group [29] , can explain the elevated abundance of this fragment in the MRM mode.
Disulfide bridge reduction
Reduction of the disulfide bridge provided additional MS data on the fragmentation behavior of desmopressin. The completeness of the reduction experiment was controlled by the injection of a 10 μg/ml solution of the reaction mixture in full-scan MS. The reduction was complete, since m/z 1,069.0 and m/z 535.5 were not recorded in the spectrum, and only monoisotopic ions at m/z 1,071.0 and m/z 536.5 were observed. Peak area ratios between singly and doubly charged pseudomolecular ions (20-25%) and peak areas were similar to those for the nonreduced species.
HCD experiments with the reduced desmopressin yielded the identification of the complete y 3-y 7 sequence, as shown in Fig. 3b .
In a second step, reduced desmopressin was analyzed by direct infusion in the triple-quadrupole mass spectrometer to obtain the most sensitive diagnostic ions to use for MRM detection. Injection of a standard solution of reduced desmopressin showed that the most abundant product ions from the precursor (m/z 536.5) were m/z 328.0, m/z 120.0, and m/z 214, which were also observed for the nonreduced species. Since no other important diagnostic ions were observed for the reduced substance and since the retention time did not differ significantly from that for the nonreduced desmopressin, disulfide bridge reduction was not considered useful for the MRM detection method.
Liquid chromatography
Chromatographic separation was achieved with a C 18 column, which allowed satisfactory peak shapes and chromatographic retention for desmopressin, the internal standard, Fig. 2 High-resolution full-scan mass spectrometry (MS) spectra of desmopressin (a), and the isotopic pattern of its base peak [M+2H] 2+ (b) and the carrier peptide. A high percentage (90%) of ACN was required to elute desmopressin, which had an average retention time (t R ) of 10.07, and the internal standard (t R 0 10.75 min). The carrier peptide AVP, which contains the terminal amino moiety, was eluted earlier (t R 03.63 min). Additionally, other desmopressin-related peptides, including the endogenous hormone oxytocin and the synthetic analogues [Lys 8 ]-vasopressin and terlipressin were analyzed to further investigate method selectivity. The results, also summarized in Table 1 , demonstrated that the chromatography was sufficient to separate desmopressin from these peptides. In fact, oxytocin was eluted at 9.88 min, [Lys 8 ]-vasopressin at 3.50 min, and terlipressin at 3.76 min.
Sample preparation
Since no LC-MS-based method for detection of desmopressin in plasma has been described previously, the sample preparation procedures available from the literature were all related to the function of immunoassays. These approaches are based mainly on previous work by Lundin et al [21, 22] . Desmopressin is a small, highly basic peptide, resulting in good solubility, without a significant tertiary structure that can undergo denaturation during protein precipitation. Therefore, Lundin et al. [21] successfully used protein precipitation with ice-cold acetone for sample cleanup. To optimize this protein precipitation step, the application of acetone, MeOH, saturated (NH 4 ) 2 SO 4 , and ethanol [30] was evaluated during method development. Deproteination of the samples using saturated (NH 4 ) 2 SO 4 gave the best results regarding S/N response. Additionally, omitting the use of an organic solvent to precipitate bulk proteins avoids the requirement to evaporate the deproteinated sample before application of SPE in the next step. Finally, the use of protein precipitation allowed a fivefold increase of the MS response compared with samples that were processed only with SPE. To further decrease the sample preparation time, centrifugation for 15 and 30 min instead of 60 min was considered; however, owing to the shorter centrifugation time, deproteination was less complete. Using centrifugation devices with a higher speed would allow to further shorten centrifugation times.
SPE was considered to further concentrate and desalt the samples. In particular, cation-exchange columns were investigated, because desmopressin is a basic peptide with a pK a of approximately 12. Mixed-mode ion-exchange (MCX) columns were initially investigated. However, desmopressin could not be recovered from this type of column during the elution step since this type of column is only applicable for weak basic compounds. MW molecular weight, ISTD internal standard WCX columns proved to be particularly suitable for the cleanup of strong basic compounds, allowing, compared with octadecyl (C 18 ) and hydrophilic-lipophilic balance (HLB) sorbents, acid and slightly basic matrix components to be eliminated efficiently. This resulted in a higher grade of purification.
Since the WCX protocol requires a basic pH to load the samples on the SPE column, the (NH 4 ) 2 SO 4 saturated solution was basified with NH 4 OH (pH 9.2). No differences in desmopressin responses were registered for protein precipitation compared with the nonbasified (NH 4 ) 2 SO 4 saturated solution. The presence of 20% water in the elution solvent, resulting in a longer evaporation time, guaranteed the best results in terms of sensitivity.
Choice of internal standard and carrier peptide [Deamino-Cys 1 , Val 4 , D-Arg 8 ]-vasopressin was chosen as the internal standard since it has a chemical structure, pK a , and retention time (Δt R ≈0.7 min) very similar to those of desmopressin, and therefore has similar behavior during the entire analytical process. Since the degree of adsorption of a peptide or protein is not always predictable, several precautions were adopted to prevent this phenomenon occurring, including the use of low-binding plastic and the use of a carrier peptide. AVP was considered as a suitable carrier peptide for working solutions since it has a retention time (Δt R ≈6.4 min) very different from that of the target analyte, which means no interferences with its detection, and, additionally, low cost for the standard reference. We registered only a slight decrease (approximately 10%) in the MS response when diluted working solutions of 10 ng/ml desmopressin, not containing AVP as the carrier peptide, were analyzed, whereas no significant differences were recorded when AVP was added to the plasma sample (2.5 ng/ml) at the beginning of the sample preparation. Hence, desmopressin adsorption did not occur or was negligible during sample preparation.
Additionally, the stability of the desmopressin working solution stored at 4°C was tested by preparing a new solution (10 pg/ml) every month and comparing it with the previous solution by LC-MS analysis. After 4 months, no significant difference was noticed in the peak areas of the various solutions. Moreover, the desmopressin working solution was found to be stable after incubation at 56°C for 6 h.
Method validation
The method showed an LOD of 50 pg/ml, with an S/N greater than 3 for the three transitions in all plasma samples that were analyzed. Maximum tolerance windows (percentage of base peak m/z 328.0) were set at ±10% (absolute) for m/z 120.0 and ±5% (absolute) for m/z 214.0, according to the WADA identification criteria for LC-MS qualitative assays [31] that recommend the use of a minimum of two transitions for MRMbased methods. Nevertheless, using only one transition is also allowed. According to the abundance recorded using the product ion at m/z 328.0, we estimated the average extraction efficiency (n010) of the preparation as 40% (±4%). Signal reduction due to ion suppression in the ESI source (n010) was limited to 5% (±14%).
The method also exhibited good selectivity since the related peptides had different retention times, as shown in Table 1 . Mass overlapping for MS detection was avoided, thereby ensuring analytical selectivity. AVP, [Lys 8 ]-vasopressin, and The method can be used for the analysis of an elevated number of samples per batch, and the whole analysis can be performed in a single day, since the only time-consuming step (evaporation of the SPE eluate) requires only a few hours.
The plasma/serum cross-validation demonstrated that desmopressin can also be detected in serum at the same level as in plasma (LOD 050 pg/mL), but only by the diagnostic product ions at m/z 328.0 and m/z 214.0. Surprisingly, the diagnostic ion at m/z 120.0 was an interferent in all serum samples. This interference was also present in the blank serum samples (data not shown). Hence, the use of plasma instead of serum resulted in higher selectivity of the method.
Method application
The suitability of our method was evaluated by the analysis of seven plasma samples from patients who had received desmopressin. Four patients received desmopressin intranasally, two received desmopressin orally, and one received desmopressin intravenously. The administered dose and collection times are summarized in Table 2 . Detection of desmopressin after oral administration could not be achieved, even taking into account only the most abundant transition (m/z 535→328, LOD010 pg/ml). Indeed, orally administered desmopressin has very low bioavailability. Osterberg et al. [19] reported maximum plasma levels below 50 pg/ml (t090 min) after oral administration of a therapeutic dose of 240 μg. Similarly, desmopressin was not detectable after nasal administration. The lower dose (approximately 10 μg) and the generally lower bioavailability of this type of formulation could explain the nondetection. After intravenous administration of a 20-μg dose, desmopressin could be detected in an unambiguous way (Fig. 4b) .
It can be concluded that desmopressin detection in plasma related to antidoping analysis is not realistic after oral or intranasal administration, in particular since oral administration has been shown to effect hematocrit values [12] . Intravenous application seems unlikely owing to its invasive nature. Hence, it will be necessary to consider other Samples were all prepared and analyzed according to the assay described. RT retention time detection strategies to increase the possibility to detect the misuse of this peptide by LC-MS. According to Agerso et al. [20] , an important fraction of desmopressin is eliminated from the body via renal clearance. Hence, urinary detection of desmopressin will be investigated further.
Conclusions
For the first time a sensitive LC-ESI-MS/MS method for the detection of desmopressin in human plasma for doping purposes was described. Validation of the method showed an LOD of 50 pg/ml when three transitions were considered, and 10 pg/ml when only the most abundant transition (m/z 328) was monitored. The method also exhibited good selectivity and specificity. Application of the method to administration samples showed that desmopressin was detectable when administered intravenously, but not after oral and intranasal administration. The results of the analysis of the administration samples are in agreement with the literature describing low bioavailability and short plasma half-lives after oral and intranasal application, hampering its detection.
